Indeed, although several clinical studies have explored the effects of targeted therapies alone or in combination with chemotherapies for gastric cancer, currently only ramucirumab (anti-VEGFR2) and trastuzumab (anti-ErbB2) have been approved as gastric efficient targeted drugs (63). This evidence concerns the gene KDR and gastric cancer.